Domača stranABBV34 • BVMF
add
Abbvie Inc BDR
Prejšnji trg. dan.
62,90 R$
Dnevni razpon
62,90 R$ - 63,90 R$
Letni razpon
54,36 R$ - 79,10 R$
Tržna kapitalizacija
322,03 mrd. USD
Povprečni obseg
5,63 tis.
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | mar. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 13,34 mrd. | 8,39 % |
Stroški poslovanja | 5,28 mrd. | 8,44 % |
Čisti dohodek | 1,29 mrd. | −6,06 % |
Čista dobičkovnost prihodkov | 9,64 | −13,31 % |
Earnings per share | 2,46 | 6,49 % |
EBITDA | 6,10 mrd. | 11,89 % |
Efektivna davčna stopnja | 22,40 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | mar. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 5,18 mrd. | −71,35 % |
Skupna sredstva | 136,16 mrd. | −8,54 % |
Skupne obveznosti | 134,70 mrd. | −4,35 % |
Celoten lastniški kapital | 1,46 mrd. | — |
Shares outstanding | 1,77 mrd. | — |
Razmerje P/B | 78,62 | — |
Donosnost sredstev | 7,48 % | — |
Donosnost kapitala | 14,21 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | mar. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 1,29 mrd. | −6,06 % |
Denar iz dejavnosti | 1,64 mrd. | −59,53 % |
Denar iz naložb | −735,00 mio. | 92,33 % |
Denar iz financiranja | −1,26 mrd. | −111,63 % |
Neto sprememba denarnih sredstev | −349,00 mio. | −106,64 % |
Prost denarni tok | 1,12 mrd. | −73,12 % |
Vizitka
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. Its major products are: Humira, approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis and administered via injection; Skyrizi, an interleukin-23 inhibitor also used to treat autoimmune diseases; Rinvoq, used to treat arthritis; and Botox. Its other major products include Imbruvica to treat cancer, Vraylar to treat schizophrenia and bipolar disorder, Venclexta to treat leukemia and lymphoma, Mavyret to treat Hepatitis C, and Epkinly, a blood-cancer therapy developed in partnership with Genmab. The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis. The company's pipeline also includes drug candidates for Parkinson's disease including Vyalev and tavapadon.
The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. Wikipedia
Datum ustanovitve
10. apr. 2012
Sedež organizacije
Spletno mesto
Zaposleni
55.000
